On Backing Semble: The Orchestration Platform for Modern Healthcare
Despite years of attempts at digital transformation, healthcare remains a tangle of disconnected point solutions.
Walk into most private clinics in the UK or France, and you will find clinicians juggling a booking tool from one vendor, a billing module from another, a clinical notes system from a third, prescribing somewhere else again, and a portal bolted on top that none of them really use. The doctor's day is built around the seams between these tools, not the work itself.
That is the problem Semble was founded to fix. And this is why Revaia is leading its Series C funding round.
The press release provides the basic details of the deals. However, we want to break down the motivation behind our investment in Semble. At a time when all software investments demand extra scrutiny amid AI’s relentless advance across every sector, we are backing a company that we believe will become the operating system for modern European healthcare.
Our thesis: own the record, own the workflow
Semble is replacing that fragmented stack with one platform. Bookings, electronic health records, e-prescribing, billing, patient communications, and clinical workflows all sit on a single data model with a single source of truth. It is not a portal stitched onto legacy systems, nor is it a bolt-on. It's an orchestration platform that brings all of these previously disconnected systems together. Rather than attempting to own everything, the company’s flexible platform is built to let doctors connect their technology across the entire patient journey.
Once a clinic is on Semble, every patient interaction, every clinical note, and every payment runs through the platform. That is what we mean by system of record, and in software, the system of record is the layer that compiles. It owns the data. It owns the workflow. It owns the surface where every other tool, including every AI tool, eventually has to plug in. Semble already supports more than 1,700 healthcare businesses across 80 specialties, with over 16,000 professionals using the platform daily and 10 million patients managed through it. The company has raised $27m to date, including a $15m Series B in October 2024, and customers report up to 75% reductions in administrative time and a doubling of patient consultations.
Why now
The UK has 7.5 million people on NHS waiting lists, and government policy is openly leaning on the private sector to clear them. Legacy practice management systems were built for a world without smartphones, let alone large language models, and they are visibly breaking under the load. Private capacity is being asked to do more than ever before, with the same staff and the same hours in the day.
The companies that built the last generation of clinical software are not going to provide what comes next. They are bolting AI features onto architectures that were never designed to be interoperable, and most of those features are surface treatments on a foundation that cannot support them.
The AI defensibility argument
Semble's AI is the orchestration platform. Ambient scribing, clinical coding, triage, summarization, and revenue cycle automation can all be trained and run on first-party longitudinal data within a regulated, consented environment. The company has spent close to three years building a centralized AI layer, with clinical safety, governance, and evaluation built in, so product teams can ship new AI features without rebuilding the compliance scaffolding each time. UK GDPR and ISO 27001 are built into the platform with EU AI Act readiness on the roadmap.
The team's strategic choice is notable. They are explicitly not trying to build "yet another scribing LLM." They have concluded that the durable position will be the orchestration layer that any AI tool needs to plug into. Best-in-class scribes, diagnostic engines, and analytics tools integrate via Semble, which orchestrates them.
The companies building AI on top of Semble's data layer end up paying rent. Semble compounds.
The team
Semble was founded in 2018 by Christoph Lippuner and Mikael Landau.
The founders previously built and sold a company to Just Eat, so they bring real exit pedigree and operator credibility. Just as importantly, that business taught them how to serve a large, fragmented base of small independent operators, and how to build software those users adopt by choice. Private healthcare looks much the same: thousands of independent clinics, each running a small business of its own.
But the creation of Semble is also intimately linked to the difficult personal hardships experienced by the co-founders, which pushed them to want to transform the healthcare system out of deep empathy.
Christoph's mother was diagnosed with cancer around the same time the two friends were selling their first business. It was an extremely traumatizing journey for his mother and the whole family. Faced with this hardship, Christoph asked himself fundamental questions: he wondered what had gone wrong, how it had come to this, and if this situation could have been avoided, particularly through earlier screening.
At the same time, Michael went through a very similar ordeal with a member of his own family, involving a different condition but a similarly difficult situation.
Instead of just blaming the medical system for these tragedies, they felt a need to get actively involved to change things. By immersing themselves in this new sector to understand the daily reality of clinicians, they noticed that healthcare professionals spent up to half of their time on computer systems that were completely "not fit for purpose" and were actually "working against them". It was these major technological inefficiencies that led to the delays and tragic situations their own families had experienced.
This is why Semble was truly "born out of empathy for healthcare professionals". The founders created this software not because they came from a medical background, but because they wanted to fix broken tools in order to free up doctors' time and prevent other patients from suffering diagnostic delays.
Today, Christoph runs the company as CEO, while Mikael serves as Chief Product Officer. The team has grown to around 140 people, with more than half working in product and engineering, across the UK, France, and the rest of Europe, representing 25 nationalities.
Where it goes next: upmarket
Semble's wedge was small private practices, single doctors, and clinics of two or three clinicians. The platform is now ready for what comes after the wedge. Multi-site groups, specialist chains, independent hospitals, and larger healthcare groups are already onboarding. We saw a meaningful inflection in enterprise traction during 2025, with mid-market already established and the first enterprise customers giving us confidence that the architecture scales without losing the product simplicity that made it work for SMBs in the first place.
Larger customers mean longer contracts, higher annual contract values, and deeper integrations with everything from hospital systems to insurance back-ends. Land-and-expand becomes land-and-anchor.
Where it goes next: France
France is the other expansion lever, and the one we are most personally invested in. Semble has been operational in France since 2024, with a local entity, a French-language platform, and early commercial traction with multidisciplinary clinics.
France is structurally attractive for a system of record like Semble. The private specialist segment is large. Incumbent software is fragmented and tired. Digitization mandates are accelerating, with regulatory frameworks such as Ségur and HDS hosting requirements driving the market toward modern, compliant platforms. Semble has achieved the maturity in less than a year to meet these complex requirements.
The French reference point most readers will reach for is Doctolib, and the comparison is worth taking seriously, though it is more nuanced than it first looks.
Doctolib has shown the scale of value in modernizing European healthcare infrastructure, and the investment and attention the category has drawn validates the size of the opportunity. Semble is focused on a distinct part of that picture: the clinical and practice-management layer for SMB and mid-market providers, where the day-to-day clinical workflow lives. The structural tailwind, with clinics moving onto modern, connected software, lifts the whole category, and Semble's role is to be the system clinicians run their practice on.
Why we are backing it
This is not Revaia's first investment in European healthcare software. Our experience with Hublo and what we have seen up close across the category has strengthened our conviction that the durable winners share three traits: they own the workflow, they treat compliance as a feature rather than a tax, and they build solutions aligned with real-world needs of clinicians. Semble has all three.
Our job in this round is straightforward. We bring pattern recognition from healthcare software at scale, hands-on experience helping European companies expand across borders, and a network of partners to help the company scale through this next stage. Semble already has the product, the customers, and the team.
We are backing the platform that we think will define the next decade of European clinical software.